Promoter methylation-associated loss of ID4expression is a marker of tumour recurrence in human breast cancer

BMC Cancer

Table 2 Clinicopathological parameters in relation to ID4 promoter methylation

Variable	ID4Methylation
	n^a	Positive	Negative	P-value^d
Total	170	117	53
*Clinicopathological parameters:*
Age at diagnosis
<50 years	51	34	17	0.821
≥ 50 years	111	76	35
Tumour size^b
pT1	62	24	44	0.247
pT2-4	91	27	7
Lymph node status^b
pN0	74	43	31	0.030
pN1-3	62	47	15
Histological grade
G1	14	10	4	0.944
G2	79	52	27
G3	61	42	19
Histological type
invasive ductal	129	87	42	0.940
invasive lobular	18	12	6
other	12	8	4
Oestrogen receptor status
negative (IRS^c 0–2)	52	35	17	0.900
positive (IRS 3–12)	101	69	32
Progesterone receptor status
negative (IRS 0–2)	57	39	18	0.920
positive (IRS 3–12)	96	65	31
ID4 mRNA expression x-fold
FC<2	8	0	8	<0.001
FC≥2	38	31	7

^a Only female patients with primary, unilateral, invasive breast cancer were included. Significant P- values are marked in bold face. ^bAccording to TNM classification by Sobin and Wittekind [37]. ^c IRS = Immuno-reactive score according to Remmele and Stegner [38]. ^dFisher's exact test. Significant P- values are marked in bold face.

ISSN: 1471-2407